Welcome to our dedicated page for Zomedica SEC filings (Ticker: ZOMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Zomedica Corp. (ZOMDF) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret the information. Zomedica is an animal health company focused on diagnostic, therapeutic, and monitoring devices for equine and companion animals, and its SEC filings offer detailed insight into how it reports financial performance, risks, and strategic priorities.
Investors can use this page to review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment discussions for diagnostics, therapeutic devices, and development services, as well as commentary on consumable and capital revenue, margins, liquidity, and operating expenses. Current reports on Form 8-K, such as the filing dated November 4, 2025 referencing a press release on quarterly results, disclose material events and financial updates between regular reporting periods.
The platform also surfaces proxy statements and other governance-related documents, where available, and Form 4 insider transaction reports that show purchases and sales by directors and officers. These documents can be important for understanding executive incentives and ownership changes.
AI-powered tools on this page summarize lengthy filings, highlight key sections, and explain complex accounting or risk disclosures in plain language. Real-time connections to the SEC’s EDGAR system help ensure new filings appear promptly, so users can quickly locate the latest 10-K, 10-Q, 8-K, and Form 4 documents for Zomedica. This structure allows both individual and professional investors to navigate Zomedica’s regulatory history and evaluate its reported progress in animal health diagnostics and therapeutics.
Zomedica Corp. director Johnny D. Powers reported buying a total of 500,000 shares of common stock in open-market transactions. He acquired 391,129 shares at an average price of $0.113 per share and 108,871 shares at $0.112 per share, increasing his direct ownership stake through personal share purchases.
Zomedica Corp. CEO and director Larry C. Heaton II reported an open-market purchase of 250,000 shares of the company’s common stock at $0.11 per share. Following this transaction, his direct ownership increased to 1,250,000 common shares.
Zomedica Corp. reported record first quarter 2026 revenue of $8.8 million, up 35% from $6.5 million a year earlier. Growth was driven by 73% higher Diagnostics sales, 22% growth in consumables, steady Therapeutic Device revenue at $5.8 million, and contributions from its Development Services segment.
Gross margin was 62%, while operating expenses excluding prior-year impairments fell 21% to $10.4 million. Net loss narrowed sharply to $4.5 million from $63.8 million, and Adjusted Non-GAAP EBITDA loss improved to $2.4 million from $5.7 million. Cash, cash equivalents, and available-for-sale securities totaled $47.5 million, with quarterly cash burn of $5.7 million, down 15% year over year.
Zomedica Corp. reported higher revenue but a small net loss for the quarter ended March 31, 2026. Net revenue rose to $8,799 from $6,500 a year earlier, driven mainly by Therapeutic Devices and new Development Services revenue.
Gross profit increased to $5,484 from $4,407, while operating expenses fell sharply because the prior-year period included large impairment charges. The company posted a net loss of $4,534, a major improvement from a $63,809 loss in the prior-year quarter.
Zomedica ended the quarter with $9,369 in cash and cash equivalents and $44,965 of investment securities, against total liabilities of $10,588. All three segments—Diagnostics, Therapeutic Devices, and Development Services—generated revenue, with U.S. customers providing most sales.
Zomedica Corp. is calling a virtual Annual Meeting of Shareholders on June 10, 2026 to conduct key governance votes. Shareholders of record at the close of business on April 21, 2026, when 979,949,668 common shares were outstanding, may attend and vote online.
Shareholders will be asked to elect eight directors, ratify Grant Thornton LLP as independent registered public accounting firm for 2026, approve an advisory say‑on‑pay vote on named executive officer compensation, and approve a By‑Law amendment clarifying quorum requirements for adjourned meetings.
The Board recommends that shareholders vote FOR all four proposals and explains detailed procedures for registered and beneficial holders to vote by proxy, Internet, telephone, or during the live webcast. The proxy also outlines executive and director pay programs, stock option grants and a 2024 cash‑settled stock appreciation rights plan.
Zomedica Corp. is soliciting proxies for its virtual Annual Meeting of Shareholders to be held on June 10, 2026. Shareholders of record as of April 21, 2026 may vote. The meeting agenda includes the election of eight directors, ratification of Grant Thornton LLP as the independent registered public accounting firm, an advisory vote on named executive officer compensation, and an amendment to the Company By-Laws addressing adjourned-meeting quorum procedures. The Board recommends a vote FOR each proposal. Shares outstanding as of the Record Date are listed as 979,949,668.
Zomedica reported record 2025 results, with full-year revenue rising 17% to $32.0 million and fourth quarter revenue up 33% to $10.5 million. Growth was led by its PulseVet and Assisi therapeutic devices, expanding TRUFORMA diagnostics, and a new Development Services segment that generated $3.1 million.
Gross margin remained strong at 68% for the year and reached 69% in the fourth quarter. Adjusted operating expenses fell 7% to $50.2 million, helping reduce cash burn to $18.1 million for 2025, including just $1.1 million in the fourth quarter. Liquidity was $53.3 million as of December 31, 2025.
However, a non-cash impairment charge of $55.8 million, driven by lower market capitalization, pushed net loss to $81.9 million. Even excluding non-recurring and non-cash items, Adjusted Non-GAAP EBITDA remained a loss of $17.1 million, though this improved from a $20.2 million loss in 2024.
Zomedica Corp. files its annual report describing a much larger 2025 loss and a shift in its listing venue. The animal health company, which sells diagnostic and therapeutic devices for companion animals, reported a net loss of $81,786,000 versus $46,942,000 a year earlier and an accumulated deficit of $299,773,000. Total shareholders’ equity was $115,397,000, with 979,949,668 common shares outstanding and a non‑affiliate market value of about $38.3 million. After NYSE American suspended and delisted its shares on March 4, 2025 for prolonged low price, trading moved to the OTCQB under the symbol ZOMDF. Zomedica highlights six commercial product lines, ongoing R&D spending of $7.2 million, 141 employees, and extensive competition and risk factors, including supply chain disruption, regulatory changes, cybersecurity, and continued operating losses.
Zomedica Corp. (ZOMDF) reported a new equity award to one of its directors. The director received a stock appreciation right covering 1,975,033 underlying common shares at a conversion or exercise price of $0.1 per share in a transaction on 11/17/2025 coded as an acquisition. These rights become exercisable on 11/16/2026 and expire on 11/16/2035. Following this grant, the director beneficially owns 1,975,033 derivative securities directly, all tied to Zomedica common stock.
Zomedica Corp. (ZOMDF) reported an equity award to one of its directors. On 11/17/2025, reporting person Johnny Powers acquired 1,823,107 stock appreciation rights, each linked to one share of Zomedica common stock. The rights have a conversion or exercise price of $0.10 per share, with a vesting or exercisability date of 11/16/2026 and an expiration date of 11/16/2035. Following this grant, Powers beneficially owns 1,823,107 derivative securities directly, giving him economic exposure to the same number of Zomedica common shares if the stock price rises above the exercise price.